Organisation paid for research Program year 2023 Source: CMS Open Payments

Sodeinc Inc

Neither a doctor nor a teaching hospital

Research payments

$52,853

30 payments

Through program year 2023, Sodeinc Inc is reported as receiving $52,853 in research payments, across 30 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$3,550	2
2022	Research	$5,960	5
2021	Research	$25,425	7
2020	Research	$4,475	5
2019	Research	$13,443	11

Breakdown

Who paid Research payments · program years 2019–2023

AbbVie, Inc. $52,853 30 payments

Studies the money was for Research payments · program years 2019–2023

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) $11,960 2 payments
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE) $9,520 2 payments
M11-352 $5,331 2 payments
M15-538 $3,450 3 payments
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis $2,970 2 payments
M16-043 $2,500 3 payments
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) $2,450 2 payments
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Na?ve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy $2,450 1 payment
M14-239 $2,250 4 payments
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) $2,075 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.